Zhejiang Jingxin Pharmaceutical Co (002020) Fair Value & Analysis

Healthcare · CN · Market cap 12.4B CNY

A solid business, screening 16% undervalued on our models.

What matters now

• A fairly wide model range (¥10.40 to ¥20.86) leaves room in how you read the outcome.
• Our model range runs from ¥10.40 (bear) to ¥20.86 (bull), base ¥16.69. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 70/100 (solid quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 8, 2026.

How to read this chart

60‑month range ¥6.68 – ¥21.03 · fair‑value band ¥10.40 – ¥20.86 · the ¥14.38 price screens below the ¥16.69 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 8, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Zhejiang Jingxin Pharmaceutical Co (002020) currently trades at ¥14.38, while our model-based Fair Value estimate is ¥16.69, implying the stock looks roughly 16.1% undervalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Zhejiang Jingxin Pharmaceutical Co generated revenue of 4.0B CNY at a net margin of 18.8%. Revenue declined 3.5% year over year. It earns a return on equity of 13.2%. The balance sheet holds a net cash position of 11.8M CNY. Fundamentals as of Aug 8, 2026

Our scenario range runs from ¥10.40 (bear case) to ¥20.86 (bull case); at ¥14.38, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 16%, 002020 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥19.49) versus Asset-Based (¥4.54). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally.

Full company description

Zhejiang Jingxin Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products and medical devices in China and internationally. The company offers antihypertensive, antibiotics, quinolones, gastrointestinal promotion, antidiabetic, antiepileptic, antihistamine, H+ pump depressant, antihyper cholesterolemia, histamine H2 receptor blockader, antihyper cholesterolemirs, antidepressant, cephalosporin, and biopharma products; and API products, including ciprofloxacin, ciprofloxacin hydrochloride, ciprofloxacin lactate, levofloxacin hemihydrate, levofloxacin hydrochloride, levofloxacin lactate, enrofloxacin, enrofloxacin hydrochloride, simvastatin, rosuvastatin calcium, pitavastatin calcium, ticagrelor, rivaroxaban, apixaban, cisapride, levetiracetam, brivaracetam, sertraline HCI, rivastigmine bitartrate, pramipexole dihydrochloride, memantine hydrochloride, empagliflozin, dapagliflozin, marbofloxacin, and moxifloxacin. It also provides intermediates; and medical display products, such as diagnostic medical displays, surgical medical displays, clinical medical displays, medical large screens, medical integrated machines, ultrasonic medical displays, and other products. The company was formerly known as Zhejiang Jingxin Pharmaceutical Factory and changed its name to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000. Zhejiang Jingxin Pharmaceutical Co., Ltd. was founded in 1990 and is headquartered in Xinchang, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Zhejiang Jingxin Pharmaceutical Co reported revenue of ¥4.1B in FY2025 versus ¥3.5B in FY2021, a compound +4.1%/yr. Reported net income was ¥758M in FY2025, compounding +5.5%/yr from FY2021.

Watch 002020: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 8, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.